908 Devices posts 35% Q3 revenue growth and record 308 device placements, raising the low end of 2026 revenue guidance to $68.5 million. See more on MASS stock.
Motley Fool Press Release.
BURLINGTON, Mass., September 01, 2026--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.
908 Devices (NASDAQ:MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said
This is the newest page. Registered accounts read further back.